Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K7HU
|
|||
| Former ID |
DAP000423
|
|||
| Drug Name |
Ciclesonide
|
|||
| Synonyms |
Alvesco; Omnair; Omnaris; Osonase; Osonide; Alvesco HFA; Ciclesonide [INN]; Omnaris HFA; RPR 251526; Alvesco (TN); BTR-15; BTR-15K; BY-9010; BYK-20426; KS-1165; Omnaris (TN); Omniair (TN); TBN-15; B-9207-015; Ciclesonide (JAN/USAN/INN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8] | Approved | [1], [2], [3], [4] | |
| Obstructive airway disease [ICD-11: CB40.Y] | Approved | [1], [2], [3], [4] | ||
| Therapeutic Class |
Antiallergic Agents
|
|||
| Company |
Altana Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H44O7
|
|||
| Canonical SMILES |
CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6
|
|||
| InChI |
1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1
|
|||
| InChIKey |
LUKZNWIVRBCLON-GXOBDPJESA-N
|
|||
| CAS Number |
CAS 126544-47-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7848766, 12014485, 14763472, 14910303, 17194708, 43529548, 50069804, 50113016, 53790514, 57371818, 75476862, 92719025, 93307925, 93815124, 126592968, 126621149, 126652709, 135211289, 135805250, 137002365, 137619495, 144206039, 152134121, 160668474, 162183036, 162258877, 164788141, 175266964, 184545966, 187051772, 187072300, 196106072, 210279779, 210282102, 223657022, 224423934, 226395815, 251915931, 251917279, 252215142, 252347327
|
|||
| ChEBI ID |
CHEBI:31397
|
|||
| ADReCS Drug ID | BADD_D00460 | |||
| SuperDrug ATC ID |
R01AD13; R03BA08
|
|||
| SuperDrug CAS ID |
cas=141845821
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Corticosteroid-binding globulin (SERPINA6) | Target Info | Binder | [5], [6] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7469). | |||
| REF 2 | 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53. | |||
| REF 5 | Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab. 2000 Jan;85(1):361-7. | |||
| REF 6 | A Leu----His substitution at residue 93 in human corticosteroid binding globulin results in reduced affinity for cortisol. J Steroid Biochem Mol Biol. 1992 Aug;42(7):671-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.